Insulin Pricing Litigation
The causation theory posits that inflated insulin prices, driven by alleged rebate schemes and price inflation practices by manufacturers and PBMs, reduce patient access to affordable insulin. This leads to health deterioration, including diabetic ketoacidosis, hyperglycemia, and other complications, due to rationing or delayed treatment. Scientific analyses and expert opinions cited in the litigation support the link between high prices and increased morbidity and mortality among diabetic patients, emphasizing that the harm extends beyond financial costs to tangible health risks.
514
Pending actions
615
Total actions filed
Active
Status
08/03/2023
Established
Filing deadline
Specific filing deadlines or statutes of limitations are not explicitly listed in publicly available court documents as of March 2026. Procedural schedules suggest deadlines are still being set or clarified by the court, with procedural notices from 2023-2025 indicating ongoing case management.
Who qualifies
Plaintiffs include individuals, governmental entities, or self-funded plans who have paid inflated insulin prices during the relevant period, likely involving purchases of specified insulin products from Eli Lilly, Novo Nordisk, or Sanofi. Specific medical conditions or diagnoses are not explicitly detailed in publicly available documents, but the harm is linked to reduced access to insulin leading to diabetic complications. The criteria probably include having purchased insulin during the period affected by the alleged scheme, with no explicit dosage or exposure thresholds publicly specified.
Products involved
- Humalog (insulin lispro)
- Basaglar (biosimilar insulin glargine)
- NovoLog (insulin aspart)
- Levemir (insulin detemir)
- Tresiba (insulin degludec)
- Lantus (insulin glargine)
- Apidra (insulin glulisine)
Alleged injuries
- Diabetic ketoacidosis
- Hyperglycemia
- Diabetic complications due to insulin rationing or delayed treatment
- Increased morbidity and mortality among diabetic patients
Bellwether trials
Bellwether trials are scheduled for early 2026, with specific dates including January 20, 2026, March 3, 2026, and May 11, 2026, presided over by Judge Leigh Martin May. No verdicts or settlement figures have been publicly disclosed as of March 2026, and ongoing case management indicates trials are active but outcomes are pending.
Lead counsel
- Levin Papantonio Rafferty (Troy Rafferty, Brandon Bogle)
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
